| Trial ID: | L3005 |
| Source ID: | NCT01262586
|
| Associated Drug: |
Vildagliptin
|
| Title: |
Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type II Diabetes Mellitus
|
| Interventions: |
DRUG: Vildagliptin|DRUG: Glimepiride
|
| Outcome Measures: |
Primary: Change in Glycemic profiles between vildagliptin and glimepiride, Baseline and treatment Day 5, 24hr continuous glucose measurements | Secondary: Glucose Fluctuation before and during treatment, Baseline and treatment Day 5, 24hr continuous measurements
|
| Sponsor/Collaborators: |
Sponsor: Novartis Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2010-11
|
| Completion Date: |
2011-03
|
| Results First Posted: |
|
| Last Update Posted: |
2016-11-18
|
| Locations: |
Novartis Investigative Site, Mainz, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT01262586
|
